Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $132.86 Consensus Price Target from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $132.86.

LNTH has been the topic of a number of research analyst reports. Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the 4th quarter worth $27,000. Summit Securities Group LLC purchased a new position in shares of Lantheus during the 4th quarter worth $37,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares during the period. Finally, World Investment Advisors LLC purchased a new stake in Lantheus in the 3rd quarter valued at about $60,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $106.34 on Wednesday. The stock has a market capitalization of $7.28 billion, a price-to-earnings ratio of 17.69 and a beta of 0.44. Lantheus has a 12 month low of $56.44 and a 12 month high of $126.89. The firm’s 50 day simple moving average is $90.43 and its 200-day simple moving average is $96.80.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.